Airport operator APAC has won access to Q&A logs in a data room set up by shareholder Dexus for prospective buyers, in a dispute over whether the real estate asset manager breached a confidentiality deed.
Harvey Norman says it should not be fined more than $24 million for running misleading ads touting interest-free financing, telling a court it should not be punished for “unattractive” remarks its founder made in the media about the legal system.
The Takeovers Panel has agreed to hear Mayne Pharma’s latest dispute with Cosette over the US drug maker’s attempts to walk away from their $672 million merger agreement and extended the timeline for completing the deal.
Piper Alderman has been pulled back into a costs dispute after a judge found the director of dairy company Care A2 had an arguable defence and set aside a default judgment for the law firm.
The owner of Sydney developer Coronation Property has sued Fairfax for defamation over a Sydney Morning Herald story that allegedly linked him to arson attacks on two childcare centres and the home of YouTuber Jordan Shanks.
ASIC on Thursday pushed for penalties totalling $85 million against Harvey Norman and Latitude Finance, after an appeals court found the retailer’s ads touting interest-free financing were misleading.
The trustee for super fund Cbus has agreed to pay a $23.5 penalty after admitting liability in the corporate regulator’s case over excessive delays in processing $20 million in death and disability claims.
A judge has approved a “modest” $8.7 million settlement in a class action against medical device maker Exactech over allegedly defective joint replacements, saying the settlement was fair and reasonable given the limited assets of the company, whose parent has filed for bankruptcy in the US.
A former managing director of ratings agency Nielsen, who alleges she was unfairly dismissed after her husband was fired from the company, has lost her bid to be temporarily reinstated.
Mayne Pharma has secured an extension of the deadline for securing Foreign Investment Review Board approval of its $672 million tie-up with US drug maker Cosette.